<DOC>
	<DOCNO>NCT00408915</DOCNO>
	<brief_summary>The aim study evaluate long-term efficacy , local tolerability safety Lisuride apply subcutaneous infusion compare placebo patient advance Parkinson 's disease motor fluctuation `` OFF '' period refractory conventional treatment .</brief_summary>
	<brief_title>Continuous Application Lisuride Parkinson 's Disease Subcutaneous Infusion</brief_title>
	<detailed_description>The current CALIPSO study investigate efficacy continuous lisuride infusion optimize previous oral therapy patient experience motor fluctuation OFF period and/or strenuous dyskinesia four hour per day . The control core study schedule last six week . Within study previous oral therapy either continue capsule/blinded design ( placebo infusion go concurrently ) oral therapy substitute lisuride infusion ( placebo capsule administer time ) . After control core study patient whose condition worsen study ( mean patient placebo infusion group well , treat core study ) , give chance continue infusion therapy lisuride open extension phase .</detailed_description>
	<mesh_term>Parkinson Disease</mesh_term>
	<mesh_term>Lisuride</mesh_term>
	<criteria>Idiopathic Parkinson 's disease least 3 year ( diagnosis base UK Brain Bank Criteria ) Presence motor fluctuation ( wearingoff `` OFF '' period ) / presence troublesome dyskinesia , total daily minimum least 4 hour , despite optimized oral antiparkinsonian therapy Stable levodopa intake , i.e . least four dos levodopa per day Stable dose antiparkinsonian drug , dopamine agonist , COMT MAOB inhibitor , amantadine , anticholinergic minimum four week prior inclusion . The following oral dopamine agonist drug allow trial : pramipexol total daily dose 3,15mg , ropinirol total daily dose 24mg , cabergoline total daily dose 6mg combination Concomitant disease stable well controlled Willingness ability comply trial requirement Written inform consent Nonidiopathic Parkinson 's disease ( e.g . druginduced form secondary atypical parkinsonism MSA ) Significant neurological symptom account Parkinson 's disease History presence dementia demonstrate Minimental status examination ( MMSE &lt; 24 ) Presence major depression accord DSM IV criterion ( â‰¥ 6 month ) History presence epilepsy Presence dopaminergic psychosis Unstable severe concomitant disease ( e.g . liver disease , kidney disease clinically relevant cardiac coronary dysfunction ) Presence heart valvular fibrosis indication significant valvular stenosis / insufficiency echocardiogram History syncope and/or severe otherwise symptomatic orthostatic hypotension Present treatment neuroleptic , include atypical neuroleptic Treatment CNS active drug therapy ( e.g . sedative , hypnotic , antidepressant , anxiolytic ) unless dose stable least four week prior baseline visit Participation another trial investigational drug within last 28 day current participation another trial investigational drug Clinically significant laboratory abnormality Previous neurosurgery Parkinson 's disease Alcohol drug abuse past three year</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>75 Years</maximum_age>
	<verification_date>March 2012</verification_date>
	<keyword>Lisuride</keyword>
	<keyword>Continuous Dopaminergic Stimulation</keyword>
	<keyword>Motor Fluctuations</keyword>
	<keyword>Off-Times</keyword>
	<keyword>Troublesome Dyskinesia</keyword>
	<keyword>Parkinson 's Disease motor fluctuation OFF period and/or troublesome dyskinesia four hour per day</keyword>
</DOC>